Retapamulin

DRUG6 trials

Sponsors

GlaxoSmithKline, Ochsner Health System, University of California, Irvine, NYU Langone Health

Conditions

ImpetigoInfections, BacterialMRSAMethicillin-Resistant Staphylococcus AureusMethicillin-resistant Staphylococcus AureusSkin Infections, Bacterial

Phase 2

Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus

CompletedNCT00539994

GlaxoSmithKlineInfections, Bacterial

Start: 2007-09-30End: 2008-01-31Updated: 2016-12-15

Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus

CompletedNCT00539994

GlaxoSmithKlineInfections, Bacterial

Start: 2007-09-30End: 2008-01-31Updated: 2016-12-15

Phase 3

Retapamulin as a Decolonizing Agent for MRSA

CompletedNCT03304873

NYU Langone HealthMRSA

Start: 2017-12-01End: 2019-03-18Updated: 2020-03-19

Phase 4

Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization

WithdrawnNCT00856089

Ochsner Health SystemMethicillin-resistant Staphylococcus Aureus

Start: 2009-05-31End: 2009-10-31Updated: 2018-09-11

Retapamulin for Reducing MRSA Nasal Carriage

CompletedNCT01461668

University of California, IrvineMethicillin-Resistant Staphylococcus Aureus

Start: 2012-07-31End: 2017-12-31Updated: 2018-04-02

Unknown Phase

United States Pharmacovigilence Retapamulin-Prescribing

CompletedNCT01153880

GlaxoSmithKlineSkin Infections, Bacterial

Start: 2008-12-31End: 2012-08-31Updated: 2013-06-10

EU PV for Retapamulin-Prescribing

CompletedNCT01153828

GlaxoSmithKlineImpetigo

Start: 2008-11-30End: 2012-08-31Updated: 2013-06-10